This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lung cancer	Lysyl oxidase (LOX); serine/threonine kinase 11 (STK11; LKB1)	<i>In vitro</i> and mouse studies suggest that inhibiting LOX could help treat lung cancer. Microarray analysis of tumor tissue from lung adenocarcinoma patients showed that high LOX expression correlated with lower survival rates than low LOX expression ($p=0.0009$). In a mouse model of Lkb1-deficient lung cancer, a LOX inhibitor decreased the volume and number of tumors compared with saline control. Next steps include confirming the correlation between LOX levels and clinical-stage disease in a larger patient cohort and developing a more potent and specific LOX inhibitor.	Patented; available for licensing	Gao, Y. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Oct. 18, 2010; doi:10.1073/pnas.1004952107 Contact: Gaoxiang Ge, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China e-mail: gxge@sibs.ac.cn
SciBX 3(42); doi:10.1038/scibx.2010.1262 Published online Oct. 28, 2010				